Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADAM10 | O14672 | 20/20 | 0.83 |
| ▸ | ERBB2 | P04626 | 18/20 | 0.83 |
| ▸ | MMP2 | P08253 | 15/20 | 0.83 |
| ▸ | MMP1 | P03956 | 1/20 | 0.59 |
| ▸ | MMP9 | P14780 | 2/20 | 0.56 |
| ▸ | MMP3 | P08254 | 1/20 | 0.56 |
| ▸ | MMP8 | P22894 | 1/20 | 0.55 |
| ▸ | MMP12 | P39900 | 1/20 | 0.55 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3457696 | 1.00 | ADAM10 (0.83) | ADAM10ERBB2MMP2MMP1MMP9 | |
| SCHEMBL3457423 | 1.00 | ADAM10 (0.83) | ADAM10ERBB2MMP2MMP1MMP9 | |
| SCHEMBL3457411 | 0.95 | ADAM10 (0.84) | ADAM10ERBB2MMP2MMP1MMP9 | |
| SCHEMBL3457691 | 0.95 | ADAM10 (0.84) | ADAM10ERBB2MMP2MMP1MMP9 | |
| SCHEMBL2172920 | 0.92 | ADAM10 (0.95) | ADAM10ERBB2MMP2MMP1MMP9 | |
| SCHEMBL2172912 | 0.92 | ADAM10 (0.95) | ADAM10ERBB2MMP2MMP1MMP9 | |
| SCHEMBL2174680 | 0.92 | ADAM10 (0.98) | ADAM10ERBB2MMP2MMP1MMP9 | |
| SCHEMBL2174668 | 0.92 | ADAM10 (0.98) | ADAM10ERBB2MMP2MMP1MMP9 | |
| SCHEMBL2175240 | 0.91 | ADAM10 (0.77) | ADAM10ERBB2MMP2MMP1MMP9 | |
| SCHEMBL2175256 | 0.91 | ADAM10 (0.77) | ADAM10ERBB2MMP2MMP1MMP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150025056-A1 | SUBSTITUTED CYCLIC HYDROXAMATES AS INHIBITORS OF MATRIX METALLOPROTEINASES | INCYTE CORPORATION (US) | 2015-01-22 | — | — | US | claimed |
| US-8853243-B2 | Substituted cyclic hydroxamates as inhibitors of matrix metalloproteinases | INCYTE CORPORATION (US) | 2014-10-07 | — | — | US | claimed |
| EP-2264030-A1 | Substituted cyclic hydroxamates as inhibitors of matrix metalloproteinases | Incyte Corporation (US) | 2010-12-22 | — | — | EP | claimed |
| US-20080167288-A1 | Substituted cyclic hydroxamates as lnhibitors of matrix metalloproteinases | LNCYTE CORPORATION (US) | 2008-07-10 | — | — | US | claimed |
| US-20150025056-A1 | SUBSTITUTED CYCLIC HYDROXAMATES AS INHIBITORS OF MATRIX METALLOPROTEINASES | INCYTE CORPORATION (US) | 2015-01-22 | — | — | US | disclosed |
| US-8853243-B2 | Substituted cyclic hydroxamates as inhibitors of matrix metalloproteinases | INCYTE CORPORATION (US) | 2014-10-07 | — | — | US | disclosed |
| EP-2264030-A1 | Substituted cyclic hydroxamates as inhibitors of matrix metalloproteinases | Incyte Corporation (US) | 2010-12-22 | — | — | EP | disclosed |
| US-20080167288-A1 | Substituted cyclic hydroxamates as lnhibitors of matrix metalloproteinases | LNCYTE CORPORATION (US) | 2008-07-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150025056-A1 | SUBSTITUTED CYCLIC HYDROXAMATES AS INHIBITORS OF MATRIX METALLOPROTEINASES | MMP25, MMP2, MMP14 | ADAM10 26/4885ERBB2 3036/4885MMP2 2/4885 |
| US-20080167288-A1 | Substituted cyclic hydroxamates as lnhibitors of matrix metalloproteinases | MMP25, MMP9, MMP24 | ADAM10 25/4885ERBB2 3033/4885MMP2 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.